A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
Phase 2
60
about 1.8 years
18+
14 sites in CO, IL, MD +7
About this study
This trial is testing a treatment with fruquintinib and FOLFIRI in people with metastatic colorectal cancer. The goal is to see if this combination is effective and safe.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)
- 2.Take fruquintinib
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
fluorouracil (Antimetabolite; mimics uracil to disrupt DNA/RNA in cancer cells), chemotherapy (Antimetabolite; mimics uracil to disrupt DNA/RNA in cancer cells), irinotecan, Antidotes, Deterrents, and Toxicologic Agents (Enzyme Interactions), fruquintinib
oral (Oral Capsule), injection (Injection)
Primary: Progression-Free Survival (PFS) rate at 6 months
Secondary: Disease control response rate (DCR), Duration of response (DoR), Number of participants with treatment emergent adverse events, Overall Response Rate (ORR), Overall Survival (OS)
Oncology